• Explore /
  • Poster
  • / Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

Abstract Video & Slides Poster

Authors

null

Jose Luis Perez-Gracia

Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain

Jose Luis Perez-Gracia , Aaron Richard Hansen , Rikke Helene Loevendahl Eefsen , Carlos A. Gomez-Roca , Sylvie Negrier , Paolo Pedrazzoli , Jae-Lyun Lee , Teresa Alonso Gordoa , Cristina Suarez Rodriguez , Begona Mellado , Victor Moreno , Alejo Rodriguez-Vida , Arif Hussain , Nicole Getzmann , David Dejardin , Christophe Boetsch , Anton Kraxner , Taner Vardar , Volker Teichgräber , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03063762

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4556)

DOI

10.1200/JCO.2021.39.15_suppl.4556

Abstract #

4556

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Igor Tsaur

First Author: Brian I. Rini

First Author: David F. McDermott

First Author: Cora N. Sternberg